Magnetic Resonance Imaging Characterization and Clinical Outcomes of Dilated and Arrhythmogenic Left Ventricular Cardiomyopathies.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
14 May 2024
Historique:
received: 30 11 2023
revised: 06 02 2024
accepted: 26 02 2024
medline: 9 5 2024
pubmed: 9 5 2024
entrez: 8 5 2024
Statut: ppublish

Résumé

Nondilated left ventricular cardiomyopathy (NDLVC) has been recently differentiated from dilated cardiomyopathy (DCM). A comprehensive characterization of these 2 entities using cardiac magnetic resonance (CMR) and genetic testing has never been performed. This study sought to provide a thorough characterization and assess clinical outcomes in a large multicenter cohort of patients with DCM and NDLVC. A total of 462 patients with DCM (227) or NDLVC (235) with CMR data from 4 different referral centers were retrospectively analyzed. The study endpoint was a composite of sudden cardiac death or major ventricular arrhythmias. In comparison to DCM, NDLVC had a higher prevalence of pathogenic or likely pathogenic variants of arrhythmogenic genes (40% vs 23%; P < 0.001), higher left ventricular (LV) systolic function (LV ejection fraction: 51% ± 12% vs 36% ± 15%; P < 0.001) and higher prevalence of free-wall late gadolinium enhancement (LGE) (27% vs 14%; P < 0.001). Conversely, DCM showed higher prevalence of pathogenic or likely pathogenic variants of nonarrhythmogenic genes (23% vs 12%; P = 0.002) and septal LGE (45% vs 32%; P = 0.004). Over a median follow-up of 81 months (Q1-Q3: 40-132 months), the study outcome occurred in 98 (21%) patients. LGE with septal location (HR: 1.929; 95% CI: 1.033-3.601; P = 0.039) was independently associated with the risk of sudden cardiac death or major ventricular arrhythmias together with LV dilatation, older age, advanced NYHA functional class, frequent ventricular ectopic activity, and nonsustained ventricular tachycardia. In a multicenter cohort of patients with DCM and NDLVC, septal LGE together with LV dilatation, age, advanced disease, and frequent and repetitive ventricular arrhythmias were powerful predictors of major arrhythmic events.

Sections du résumé

BACKGROUND BACKGROUND
Nondilated left ventricular cardiomyopathy (NDLVC) has been recently differentiated from dilated cardiomyopathy (DCM). A comprehensive characterization of these 2 entities using cardiac magnetic resonance (CMR) and genetic testing has never been performed.
OBJECTIVES OBJECTIVE
This study sought to provide a thorough characterization and assess clinical outcomes in a large multicenter cohort of patients with DCM and NDLVC.
METHODS METHODS
A total of 462 patients with DCM (227) or NDLVC (235) with CMR data from 4 different referral centers were retrospectively analyzed. The study endpoint was a composite of sudden cardiac death or major ventricular arrhythmias.
RESULTS RESULTS
In comparison to DCM, NDLVC had a higher prevalence of pathogenic or likely pathogenic variants of arrhythmogenic genes (40% vs 23%; P < 0.001), higher left ventricular (LV) systolic function (LV ejection fraction: 51% ± 12% vs 36% ± 15%; P < 0.001) and higher prevalence of free-wall late gadolinium enhancement (LGE) (27% vs 14%; P < 0.001). Conversely, DCM showed higher prevalence of pathogenic or likely pathogenic variants of nonarrhythmogenic genes (23% vs 12%; P = 0.002) and septal LGE (45% vs 32%; P = 0.004). Over a median follow-up of 81 months (Q1-Q3: 40-132 months), the study outcome occurred in 98 (21%) patients. LGE with septal location (HR: 1.929; 95% CI: 1.033-3.601; P = 0.039) was independently associated with the risk of sudden cardiac death or major ventricular arrhythmias together with LV dilatation, older age, advanced NYHA functional class, frequent ventricular ectopic activity, and nonsustained ventricular tachycardia.
CONCLUSIONS CONCLUSIONS
In a multicenter cohort of patients with DCM and NDLVC, septal LGE together with LV dilatation, age, advanced disease, and frequent and repetitive ventricular arrhythmias were powerful predictors of major arrhythmic events.

Identifiants

pubmed: 38719365
pii: S0735-1097(24)00485-6
doi: 10.1016/j.jacc.2024.02.041
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1841-1851

Informations de copyright

Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures This work was supported by the Paul and Ruby Tsai Family Hypertrophic Cardiomyopathy Career Development Award (Dr Giudicessi); the National Institutes of Health/National Heart, Lung, and Blood Institute R01HL147064 and R01HL164634 (Drs Mestroni and Taylor). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Matteo Castrichini (M)

Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina, University of Trieste, Trieste, Italy, member of European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart); Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA; University of Colorado Cardiovascular Institute, Anschutz Medical Campus, Aurora, Colorado, USA.

Antonio De Luca (A)

Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina, University of Trieste, Trieste, Italy, member of European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart).

Giulia De Angelis (G)

Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina, University of Trieste, Trieste, Italy, member of European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart).

Raquel Neves (R)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Alessia Paldino (A)

Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina, University of Trieste, Trieste, Italy, member of European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart).

Matteo Dal Ferro (M)

Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina, University of Trieste, Trieste, Italy, member of European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart).

Giulia Barbati (G)

Biostatistics Unit, Department of Medical Sciences, University of Trieste, Trieste, Italy.

Kristen Medo (K)

University of Colorado Cardiovascular Institute, Anschutz Medical Campus, Aurora, Colorado, USA.

Andrea Barison (A)

Fondazione CNR-Regione Toscana G. Monasterio, Pisa, Italy.

Chrysanthos Grigoratos (C)

Fondazione CNR-Regione Toscana G. Monasterio, Pisa, Italy.

Marta Gigli (M)

Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina, University of Trieste, Trieste, Italy, member of European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart).

Davide Stolfo (D)

Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina, University of Trieste, Trieste, Italy, member of European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart); Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Francesca Brun (F)

Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina, University of Trieste, Trieste, Italy, member of European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart).

Daniel W Groves (DW)

University of Colorado Cardiovascular Institute, Anschutz Medical Campus, Aurora, Colorado, USA.

Robert Quaife (R)

University of Colorado Cardiovascular Institute, Anschutz Medical Campus, Aurora, Colorado, USA.

Ramone Eldemire (R)

University of Colorado Cardiovascular Institute, Anschutz Medical Campus, Aurora, Colorado, USA.

Sharon Graw (S)

University of Colorado Cardiovascular Institute, Anschutz Medical Campus, Aurora, Colorado, USA.

Jeffrey Addison (J)

University of Colorado Cardiovascular Institute, Anschutz Medical Campus, Aurora, Colorado, USA.

Giancarlo Todiere (G)

Fondazione CNR-Regione Toscana G. Monasterio, Pisa, Italy.

Ignazio Alessio Gueli (IA)

Fondazione CNR-Regione Toscana G. Monasterio, Pisa, Italy.

Nicoletta Botto (N)

Fondazione CNR-Regione Toscana G. Monasterio, Pisa, Italy.

Michele Emdin (M)

Fondazione CNR-Regione Toscana G. Monasterio, Pisa, Italy; Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy.

Giovanni Donato Aquaro (GD)

Academic Radiology Unit, Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.

Ramin Garmany (R)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Naveen L Pereira (NL)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Matthew R G Taylor (MRG)

University of Colorado Cardiovascular Institute, Anschutz Medical Campus, Aurora, Colorado, USA.

Michael J Ackerman (MJ)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Gianfranco Sinagra (G)

Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina, University of Trieste, Trieste, Italy, member of European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart).

Luisa Mestroni (L)

University of Colorado Cardiovascular Institute, Anschutz Medical Campus, Aurora, Colorado, USA.

John R Giudicessi (JR)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Marco Merlo (M)

Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina, University of Trieste, Trieste, Italy, member of European Reference Network for Rare, Low-Prevalence, or Complex Diseases of the Heart (ERN GUARD-Heart). Electronic address: marco.merlo@asugi.sanita.fvg.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH